Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vir Biotechnology ( (VIR) ) is now available.
Vir Biotechnology, Inc. completed a public equity offering of common stock that was initially disclosed in a regulatory filing in late February 2026. The biopharmaceutical company sold shares at $8.50 each, underscoring its continued reliance on capital markets to support its infectious disease-focused pipeline and operations.
The offering, dated February 25, 2026, covered 17,647,059 shares, with underwriters granted a 30‑day option to buy an additional 2,647,058 shares, which they fully exercised on February 26, 2026. The deal closed on February 27, 2026, resulting in the issuance of 20,294,117 shares and gross proceeds of about $172.5 million before fees and expenses, strengthening Vir’s balance sheet for future initiatives.
The most recent analyst rating on (VIR) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.
Spark’s Take on VIR Stock
According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.
The score is held back primarily by weak financial performance (ongoing large losses and significant cash burn), partially offset by a low-leverage balance sheet. Technically, the stock is in a strong uptrend but looks overextended (high RSI). The latest earnings call was a clear positive due to encouraging early clinical data and the Astellas partnership/cash runway, while valuation remains difficult to justify with negative earnings and no dividend support.
To see Spark’s full report on VIR stock, click here.
More about Vir Biotechnology
Vir Biotechnology, Inc. is a biopharmaceutical company focused on developing treatments and prevention therapies for serious infectious diseases. The company operates in the biotechnology and pharmaceutical industry, raising capital through public equity offerings to fund its research, development and potential commercialization activities in this competitive market.
Average Trading Volume: 3,149,832
Technical Sentiment Signal: Buy
Current Market Cap: $1.27B
Learn more about VIR stock on TipRanks’ Stock Analysis page.